about
The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control StudyRapid diagnostic service for patients with haematuria.The value of source data verification in a cancer clinical trial.Geographic variation in human papillomavirus-related oropharyngeal cancer: Data from 4 multinational randomized trialsA prospective study to assess the value of MMP-9 in improving the appropriateness of urgent referrals for colorectal cancerEvaluation of the accuracy of serum MMP-9 as a test for colorectal cancer in a primary care population.A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines.UK ethnicity data collection for healthcare statistics: the South Asian perspective.Options for early breast cancer follow-up in primary and secondary care - a systematic review.Pathogenesis of gall stones in Crohn's disease: an alternative explanationA randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.Making randomised trials more efficient: report of the first meeting to discuss the Trial Forge platformNeoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes - what does it all mean?FKBPL: a marker of good prognosis in breast cancer.OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.Identification of novel genetic markers of breast cancer survival.PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastaA nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities.Prospective, double-blind, placebo-controlled randomized trial of cimetidine in gastric cancer. British Stomach Cancer Group.LIHNCS - Lugol's iodine in head and neck cancer surgery: a multicentre, randomised controlled trial assessing the effectiveness of Lugol's iodine to assist excision of moderate dysplasia, severe dysplasia and carcinoma in situ at mucosal resection mA genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial.A qualitative systematic review exploring lay understanding of cancer by adults without a cancer diagnosis.Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).A review of the issues and challenges involved in using participant-produced photographs in nursing research.Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.Pulmonary rehabilitation programme for patients undergoing curative lung cancer surgery.Prevalence and treatment of hypovitaminosis D in the haemodialysis population of Coventry.Management of advanced nodal disease in patients treated with primary chemoradiotherapy.Trastuzumab-associated cardiac events in the Persephone trial.OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism.Nursing student attitudes to psychiatric nursing and psychiatric disorders in New Zealand.Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.Screening for gastric cancer by Helicobacter pylori serology: a retrospective study.PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes.Feasibility of recruitment to an oral dysplasia trial in the United KingdomPrognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial.Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
P50
Q28552519-A45B6DDD-DC7E-4FB1-A40F-DBEFE61DE1B3Q30492252-C42A2A80-F5E2-44ED-9BC3-9FA62EDEA001Q30582280-D6B69574-167F-46F1-8E03-FB0D5058ADC2Q31036080-3B26D468-6F04-42F0-A0E3-9BB4051A49B2Q33261253-D74E4E79-8E99-47DF-9972-26E1289B2D35Q33262265-9F60BE35-A39B-48F1-AEC4-B2EA66F27645Q33916833-48FA5C85-6437-4430-AC81-030A2DCCA1D5Q34209401-72ED723C-96E5-4E50-8B45-AAA80C464BD0Q34303226-18E45A83-8B06-416B-B306-D45F2CD749DCQ34378455-CDAD19A8-060A-49F7-9A20-260BA110CF51Q34546440-8A3E0FBC-E8E4-47B3-AB45-01D7E5E3DD04Q34613161-32A71E67-B632-45DD-84E0-57F593B9BD12Q35610564-2E7DC67E-D388-4C60-8617-947CEAA3D65BQ35653223-FEDA81ED-2BAF-4F74-B4B6-7B79BE8A57DAQ35782342-D735F2D5-493A-4814-AAF1-5C6F078EFD1DQ35828542-DF1E354C-77EE-4895-914A-3E2F8A91BB26Q35920893-D1DCA29B-6FA2-456C-92E9-81EC7898B1B3Q36014067-BD0AB4F0-F680-44C4-8EE9-07C2720AFB3CQ36346834-DF71E683-CB0F-4B7E-A9C2-EE135AB507EBQ36409909-20FDA930-5363-4D5E-9567-FD3C83E65A10Q36619970-8F5D4996-254B-4E2A-A2C1-C679336F136EQ37361511-D1D7396E-DAD6-4EE9-97FB-F8A45D122D91Q37568754-1A933634-B1EB-42F6-817F-F9EFDE662D26Q38069849-46448D47-BDFC-497A-8589-9B13AAC09195Q38245462-18CB130F-4475-4D5F-98DC-5E48883182F3Q38347216-FA64BAA4-E837-4F6D-9370-CC47D259DCE6Q38354358-957D04CE-A532-4542-BDF1-2F3EDD54F310Q38443954-DC9E1E46-193D-474A-99BE-37EC42271FCDQ38565076-EB2C62B5-2AB0-479A-8BCC-2506783AF55BQ38733668-B55B9697-4205-4C92-9EA2-F6EB957B591CQ38773952-376ACDA5-A764-4CD3-B9AB-1A182FD36C19Q39163356-F4C943AF-8C24-480A-95E7-806C131C40DBQ39781009-F1F59DF3-ED35-4F28-BAEE-1BAF422E9B37Q40422383-9697F898-96E5-447A-95C3-E6774CB9A4BCQ40668752-CD37D062-3DDD-42FA-8A2C-533557305EB9Q40864419-771E3C10-4B80-465F-97BD-7C8D34E6537EQ41035618-E776C321-E38E-4AA5-B4FD-89D1EF0C35D2Q42326713-520223F9-BD5B-4008-8719-FC2EAFB7EFB8Q42435532-E584F2ED-2563-4F52-8723-7D383EC5109EQ42908765-AA3645C6-A32B-435A-9FC2-569C8AFD03B5
P50
description
hulumtuese
@sq
researcher
@en
researcher
@en-gb
wetenschapper
@nl
հետազոտող
@hy
name
Janet A Dunn
@ast
Janet A Dunn
@en
Janet A Dunn
@en-gb
Janet A Dunn
@es
Janet A Dunn
@nl
Janet A Dunn
@sl
type
label
Janet A Dunn
@ast
Janet A Dunn
@en
Janet A Dunn
@en-gb
Janet A Dunn
@es
Janet A Dunn
@nl
Janet A Dunn
@sl
altLabel
Janet Dunn
@en
prefLabel
Janet A Dunn
@ast
Janet A Dunn
@en
Janet A Dunn
@en-gb
Janet A Dunn
@es
Janet A Dunn
@nl
Janet A Dunn
@sl
P106
P21
P31
P496
0000-0001-7313-4446